Authors
Latest:
Survival/Success in the Age of Too Much InformationTo get their messages out in this age of polarisation and "too much information", marketers need to shout louder, have a more dramatic point of view and gather a league of similar advocates to succeed. Al Topin sees the solution in common sense and courage.
Latest:
Minimizing Mass Tort ExposureIn today's legal climate, pharmaceutical companies are prime targets for litigation in both state and federal courts. Because they are engaged in product research and development and related complex business practices spread across many jurisdictions and because the public perceives the industry as having deep pockets, executives must be prepared for-and frankly must expect to face-the challenges of major multijurisdictional litigation.
Latest:
This Is Going to HurtThe President and Congress are sounding the alarm on the need for healthcare reform. There are several near-certainties for which pharmaceutical and biotechnology companies must be prepared as they develop forecasts and for the next five or six years.
Latest:
Executive Prophesies Vision for the FutureFor the pharma industry, the year 2002 brought unprecedented competition, pricing pressures, public scrutiny, and ever-increasing regulation, all exacerbated by a weak economy. (See "Defining Events," pages 50-56.) Although a few companies forged new partnerships and produced life-saving treatments, many more struggled to meet the industry's challenges. And no road map exists to guide them through today's continuing market pressures or to help them anticipate tomorrow's challenges.
Latest:
Patient Data Come of AgeContrary to popular belief, physicians still can't retrieve the full medical history of every patient who walks into their offices. Nor can they zap prescriptions through a clearinghouse that shows whether patients are eligible for coverage and reviews all medications they are taking to forestall drug?drug interactions.
Latest:
Inside the Doughnut HoleAn answer to your question: What does the Part D coverage gap do to drug sales?
Latest:
Managing the InnovatorInnovative products, and the research and development teams that produce them, are pharma's life blood. So it's no surprise that, according to PE's 2003 Top 50 Pharma, the largest 20 pharma companies alone spent $45.5 billion on R&D.
Latest:
The Virtues of Virtual TrainingAs the popularity of online training grows, many pharma companies are likely to implement learning management systems (LMS) that can manage the reams of data generated by training divisions in a regulated environment.
Latest:
Want to Be in a Health Plan? Think Like OnePharmacoactuarial analysis helps drug companies communicate value to health plans
Latest:
The Hispanic FactorWhat Big Pharma needs to learn-and value-about this rapidly growing US demographic
Latest:
Safe and Effective, Really?To decide on a course of treatment, patients need to be told the truth straight up
Latest:
Staying Ahead of the CurveSignificant and dramatic healthcare policy changes are likely to follow after Barack Obama takes the oath of office and the expanded Democratic congressional majority settles in. But what does the electoral outcome mean for healthcare companies and the industry as a whole?
Latest:
Data Vigilance and Validation: Lessons Learned, Future Hopes for Real-World DataBiopharma experts at the forefront of applying real-world data and real-world evidence across the product life cycle converge to discuss the lingering challenges in fully realizing the vast potential of these insights to transform the value equation.
Latest:
Rethinking the Sponsor-Investigator RelationshipWhen it comes to working with clinical research sites, pharmaceutical companies should take a page out of the automakers' playbook
Latest:
ROI and Rare Disease: Retooling the ‘Gene’ Value MachineFramework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Latest:
Reimbursement: The foundation for financial decisionsIn our quest as sales reps to provide our physician customers with a valuable sales call, it is crucial to understand what the driving forces are in healthcare delivery and how they affect these customers.
